On May 11, 2026, six insiders at Rapport Therapeutics, Inc. (RAPP) executed sales of company stock, collectively totaling approximately $65.35 million. The transactions involved the sale of 271,495 shares each, at a price of $40.12 per share, by entities including Rock Ventures V, L.P. Third, Rock Ventures VI, L.P. Third, Rock Ventures Gp V, Lp Third, Rock Ventures Gp Vi, L.P. Third, Gp Vi, Llc Trv, and Gp V, Llc Trv.
These sales follow earlier, smaller transactions by related entities on May 8, 2026, where Third Rock Ventures V, L.P., Third Rock Ventures VI, L.P., Third Rock Ventures GP V, LP, Third Rock Ventures GP VI, L.P., and TRV GP VI, LLC each sold 5,018 shares. While insider selling can be attributed to various personal financial decisions such as diversification or tax planning, a coordinated divestment by multiple insiders can sometimes draw increased scrutiny from market observers.